Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase

Diabetes Care

Volumn 34, Issue 11, 2011, Pages 2403-2405

  Bergenstal, Richard M ^a   Tamborlane, William V ^b   Ahmann, Andrew ^c   Buse, John B ^d   Dailey, George ^e   Davis, Stephen N ^f   Joyce, Carol ^g,h   Perkins, Bruce A ⁱ   Welsh, John B ^j   Willi, Steven M ^k   Wood, Michael A ^l  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MEDTRONIC INC   (United States)

^k CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^l HELEN DEVOS CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; LONG ACTING INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTIPLE DAILY INJECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SENSOR AUGMENTED PUMP; TREATMENT OUTCOME; TREATMENT PLANNING; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN INFUSION; MALE; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857070142     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1248     Document Type: Article

References (7)

1. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensoraugmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther 2010;12:249-255
2. Bergenstal RM, Tamborlane WV, Ahmann A, et al.; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320
3. American Diabetes Association Work group on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249
4. Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 3 July 2011 [Epub ahead of print]
5. Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the Real Trend study. Diabetes Care 2009;32:2245-2250
6. Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Tech 2011;5:1137-1141
7. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther 2009;11(Suppl. 1):S113-S119